Within two days, multiple pharmaceutical companies announced their transcripts, and 4 companies achieved double growth in revenue and net profit

[Pharmaceutical Network Industry News] In the past two days, a number of pharmaceutical companies have released 2022 semi-annual performance report.
Among them, Watson Bio, Lingrui Pharmaceutical, Baicheng Pharmaceutical, Huadong Medicine and other pharmaceutical companies have achieved performance growt.
Watson Bio’s net profit increased by 30% On the evening of August 10, Watson Bio announced its performance report for the first half of the yea.
In the first half of the year, the company’s operating income increased by 796% year-on-year to 348 billion yuan; net profit attributable to shareholders of listed companies increased by 39% year-on-year to 348 billion yua.
421 million yuan; non-net profit attributable to shareholders of listed companies increased by 1047% year-on-year to 481 million yua.
Judging from the batch issuance data disclosed in the semi-annual report, in the first half of the year, the subsidiary Yuxi Watson's 13-valent pneumonia conjugate vaccine received batches of 3,731,508 doses, an increase of 368% over the same period of the previous yea.
Subsidiary Yuxi Zerun bivalent HPV vaccine obtained the "Biological Product Batch Release Certificate" for the first batch of products in Ma.
In the first half of the year, a total of 884,664 doses of bivalent HPV vaccine were issued in batche.
In addition, in the first half of the year, some product production lines of Yuxi Watson underwent equipment renovation due to the rectification of the WHO-PQ project and other reason.
In addition, the adjustment of the production plan of related products resulted in a large decrease in the number of batches issued for some vaccine product.
After the rectification is completed, related products Production and batch issuance will resume graduall.
Lingrui Pharmaceutical's net profit increased by 215% On August 10, Lingrui Pharmaceutical released its 2022 semi-annual report, saying that in the first half of the year, the company's operating income increased by 186% year-on-year, or about 503 billion yuan; the net profit attributable to shareholders of listed companies increased year-on-year 215%, about 271 million yua.
Regarding the growth of performance, Lingrui Pharmaceutical stated that during the reporting period, the company coordinated and promoted various work of epidemic prevention and control, production and operation, and achieved fruitful performance in ensuring supply, adjusting structure, and increasing efficienc.
With continuous improvement, the high-quality development of generic drugs has achieved phased result.
In terms of product strategy, the high-quality development of "Two Tigers" brand plaster series products is the key work for Lingrui Pharmaceutical to optimize the market strategy and implement the brand OTC development strategy in the new stage of developmen.
In terms of product research and development, during the reporting period, Lingrui Pharmaceutical led the establishment of the Henan Provincial Institute of Traditional Chinese Medicine Modernization Industry, obtained the approval for the re-registration of lomefloxacin hydrochloride cream, and Qingshi granules were included in the 2022 National Drug Standard Improvement Project Catalo.
Baicheng Pharmaceutical’s net profit increased by 1062% On August 9, Baicheng Pharmaceutical released its 2022 semi-annual report showing that in the first half of the year, the company’s operating income increased by 791% year-on-year to 246 million yuan, and its net profit increased by 1062% year-on-year to 80213 million yua.
Baicheng Pharmaceutical stated that the main reason for the growth of the company’s operating income was the continuous expansion of the business scale, and the company obtained 39452 million yuan of equity share income after the listing of the drug in the current period, which was a substantial increase over the same period of the previous yea.
According to the data, Baicheng Pharmaceutical is a comprehensive pharmaceutical R&D enterprise with technology development as its cor.
It mainly provides various pharmaceutical companies and pharmaceutical R&D investment companies with: (1) Medical technology entrusted R&D services (CRO business); (2) R&D Technical achievement transformation service; (3) Customized R&D and production service (CDMO.
In recent years, the company has also been experimenting with new drug developmen.
It is reported that there are currently 6 innovative drug projects under development, targeting H3, CDK4/6, PI3K, PPARα/δ and other targets, and developing innovative drugs targeting new target.
Huadong Medicine's annual revenue and net profit double on August 9, Huadong Medicine announced its 2022 semi-annual report, showing that in the first half of the year, the company's operating income increased by 93% year-on-year to 1197 billion yuan; net profit attributable to shareholders of listed companies increased by 09% year-on-year to 14 RMB 100 million; non-net profit attributable to shareholders of listed companies increased by 52% year-on-year to RMB 272 billio.

Judging from the semi-annual report, the pharmaceutical business is a major source of Huadong Pharmaceutical's revenu.
In the first half of 2022, its operating income increased by 95% year-on-year to 1211 billion yuan, accounting for more than 67% of the total revenue; the accumulated net profit increased by 152% year-on-year to 198 million yua.
In the first half of the year, the total operating income of the East China Medical and Aesthetics segment was 897 million yuan, accounting for about 93% of the total revenue, an increase of 1325% year-on-year on a comparable basis (excluding Ningbo in East China.
Among them, Xinke, a wholly-owned subsidiary of domestic medical and aesthetics Limei achieved an operating income of 271 million yuan, accounting for about 30% of the revenue of the medical aesthetics segmen.
In addition, in terms of innovative products, the semi-annual report mentioned that Huadong Medicine has reserved 43 innovative drug and biosimilar drug projects under development, of which 4 products are in Phase III clinical stage and 4 products are in Phase II clinical stag.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.